Congenital Combined Bleeding Disorders, a Comprehensive Study of a Large Number of Iranian Patients

Seyed Esmaeil Ahmadi, MSc¹, Mohammad Jazebi, MSc², Gholamreza Bahoush, MD³, Mohammad Reza Baghaipour, MD², Fereydoun Ala, MD², and Shadi Tabibian, PhD¹,⁴

Abstract
Congenital combined bleeding disorders (CBDs) are extremely rare disorders which mainly occur in regions with a high rate of consanguineous marriage. These disorders can present with a variety of symptoms ranging from mucocutaneous bleeding to life-threatening episodes. This study aims to evaluate the prevalence and clinical course of Iranian patients with congenital CBDs. This study is conducted on 450 patients with CBDs who were referred to the Iranian Comprehensive Hemophilia Care Center (ICHCC) between 2010 and 2020. All these patients were diagnosed through evaluation of past medical history and coagulation laboratory investigation. Out of 450 patients, 33 were entered in this study. Having excluded cases with factor (F) V and FVIII deficiency, as well as those with hereditary combined Vitamin K dependent clotting factor deficiency (VKCFD), We found the most common CBDs to be FV-FVII deficiency (n: 6, 18.1%), together with FVII and FX deficiency (n: 6, 18.1%). The most common reason for referral of these patients to ICHCC was postoperative bleeding (14.3%). The mean of The International Society on Thrombosis and Hemostasis-Bleeding Assessment Tool (ISTH-BAT) and condensed MCMDM-IVWD bleeding assessment tool were 9.6 ± 4.79 and 9.1 ± 4.87, respectively (P < 0.005). In 10 females of reproductive age, the mean of Pictorial Bleeding Assessment Chart (PBAC) score was 649.3 ± 554. Among all patients, 23 (69.7%) received on-demand replacement therapy, whereas 5 patients (15.1%) received prophylaxis. In Iran, the coinheritance of bleeding disorders is surprisingly higher than expected. Moreover, patients with congenital CBDs may experience serious bleeding manifestations.

Keywords
combined disorder, Iran, bleeding disorders

Date received: 25 January 2021; revised: 25 January 2021; accepted: 31 January 2021.

Introduction
Congenital bleeding disorders are a heterogeneous group of disorders with an exceptionally rare prevalence far exceeding that of conventionally rare hemostatic disorders like factor (F) II or FXIII deficiencies.¹ Congenital bleeding disorders may present with a varied spectrum of clinical symptoms, ranging from mucocutaneous bleeding to life-threatening hemorrhage, such as bleeding in central nervous system (CNS), from the umbilical cord (UC), hemarthrosis, from gastrointestinal (GI) bleeding, and recurrent miscarriage.²

Among CBDs, there are 2 types of combined coagulopathies, including combined FV and FVIII deficiency (simultaneous decrease in the level of FV and FVIII) and combined vitamin K-dependent coagulation factors deficiency (VKCFD) defined as a concomitant decrease in the level of 4 (FII, FV, FVII, and FX) coagulation factor.³ Quite apart from these uncommon disorders, there are also a very few cases of other combined coagulation factors deficiencies such as FV-FVII,
Materials and Methods

Patients and Data Collection

In this study, 450 patients suffering from inherited combined hemostatic disorders and referred to ICHCC between 2010 and 2020, were evaluated. All patient data was retrieved from the clinical case notes, and the selected patients were all interviewed by our clinical staff. Patient data was recorded in a standard questionnaire focus on demographics information, result of laboratory investigation, clinical manifestations, the application of a condensed version of MCMD-1 VWD bleeding assessment tool, International Society on Thrombosis and Hemostasis-Bleeding Assessment Tool (ISTH-BAT), Pictorial Bleeding Assessment Chart (PBAC), and the management strategy adopted in these cases. Patients with FV-FVIII or VKCF deficiency were excluded from the study. Patients with an inherited combination of other bleeding disorders who had shown 2 successive abnormal coagulation laboratory investigations, after an interval of at least 6 months, with normal liver function tests and no other underlying clinical disorder, were included in the study. The medical ethics committee of ICHCC approved the study, and written consent was obtained from all patients or their parents, in the case of those under 18 years of age.

Laboratory Analysis

Following clinical assessment, all patients were referred to the ICHCC coagulation laboratory for the following assessment. Prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) which were determined using an automated coagulation analyzer (Sysmex CA 1500 coagulation analyzer, Dade Behring, Deerfield, IL, USA) with a normal range of 10 to 12 sec., 25 to 40 sec., and 15 to 19 sec., respectively. Bleeding time (BT) was determined using the Ivy method, as described by Nilsson et al.2 Platelet counts were obtained from K2 Ethylenediaminetetraacetic acid (EDTA) blood samples (KX-21 hematology analyzer, Sysmex, Kobe, Japan). Coagulation factor activity was measured by 1-stage PT and PTT-based assays, using an automated coagulation analyzer (Sysmex CA 1500 coagulation analyzer, Dade Behring, Deerfield, IL, USA). In cases with low FV levels, FVIII levels were also measured to exclude combined FV-FVIII deficiency. Platelet function assays were performed within 4 hours from the time of blood collection. Following the preparation of platelet-rich plasma (PRP) and platelet-poor plasma (PPP), common agonists including ristocetin (0.75-1.50 mg/mL), ADP (200 μg/mL), collagen (200 μg/mL), and arachidonic acid (500 μg/mL) were added. The aggregometer was calibrated using autologous PPP (equivalent to 100% aggregation) and PRP (represents 0% aggregation). The aggregation tracing was observed for 5 to 10 minutes, to monitor the lag phase, shape change, primary, and secondary aggregation, and any delayed platelet responses.

VWF activity was evaluated with the VWF: ristocetin cofactor assay (VWF: RCo) by fixed platelet aggregometry using a PAP-4 (platelet Aggregation Profiler) Bio Data Corp. (Horsham, PA, USA). For VWF antigen (VWF: Ag) assessment, an immunological method (Siemens Healthcare Diagnostic Products, Marburg, Germany) was applied. Sodium dodecyl sulfate (1.3%) agarose gels electrophoresis and a modified visualization enzymatic method were used to analyze the VWF multimers.6 Platelets CD surface markers expression was evaluated using FITC-conjugated antibodies against CD41, CD42, and CD61 (Becton-Dickinson, San Jose, USA) and analyzed using FlowJo software (Tree Star, Ashland, OR). In all cases, liver function tests (LFTs) including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALKP), and gamma-glutamyl transpeptidase (γ-GT) were performed with an autoanalyzer (Model BT3000, Biotechnica, Rome, Italy) to rule out acquired combined factor deficiency due to liver disease.

Results

Out of 450 patients diagnosed with different combined hemostatic disorders, 233 cases had VKCFD (in either hereditary or acquired form), 162 cases had FV-FVIII deficiency, 9 cases had acquired deficiency of at least 1 coagulation factor. Finally, 46 cases with inherited CBDs were recognized. Eleven patients were excluded from the study due to the availability of only 1 laboratory test result. Furthermore, 2 patients with combined afibrinogenemia and FV-leiden were also excluded Among the remaining 33 patients, 18 (54.6%) were male, and 15 (45.4%) were female. The mean age of the selected cohort of patients was 21.8 ± 14.81 years of age. The mean age at diagnosis was 14 ± 14.66. The most common CBDs were FVII and FX deficiency and FV and FX deficiency (n: 6, 18.1%) (Table 1).

Discussion

CBDs are a heterogeneous group of inherited hemorrhagic disorders with varying clinical features and laboratory findings, which have mostly been reported from regions with a high rate of parental consanguinity. CBDs are extremely rare disorders which include 2 distinct types, including FV-FVIII deficiency, and VKCFD.7 However, there are a number of reports of other multiple CBDs. This study has evaluated 35 cases of CBDs other than combined FV-FVIII and VKCF deficiency.

We describe a total 19 cases (51.4%) of combined FVII deficiency with other bleeding disorders including FVII and afibrinogenemia (15.7%), FVII-FV (31.5%), FVII-FX (31.5%), FVII-FXI (5.3%), and FVII-FXIII (5.3%) deficiencies, as well as FVII-hemophilia B (HB) (5.3%), and
| N | Sex | Age (Year) | Age of diagnosis (Year) | Disorder | First laboratory assays | Reason of diagnosis | Other clinical manifestation | BAT score | MCMD Iscore | PBAC score | Type of treatment | Parental consanguinity | Family history |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 42 | 38 | FXID + Low VWF | FXI: C: 6% | Pre-operative tests | Epistaxis | 10 | 8 | 884 | Haemate™ (CSL Behring, Marburg, Germany), TXA (OD) | Neg | Neg |
| 2 | F | 31 | 21 | FXID + Type I VWD | FXI: C: 35% | Post-dental extraction bleeding | Oral cavity bleeding | 8 | 8 | 295 | TXA (OD) | Neg | Neg |
| 3 | M | 27 | 6 | FXID + Low VWF | FXI: C: 28% | Post-dental extraction bleeding | Oral cavity bleeding | 7 | 6 | – | Haemate™ (CSL Behring, Marburg, Germany) (OD) | Neg | Neg |
| 4 | M | 46 | 38 | FV-FVII | FV: C: 32% | Positive family history | Oral cavity bleeding | 8 | 8 | – | rFVII (AryoSeven™, Aryogene, Iran) (OD) | Pos | Pos (Son #4 and #5) |
| 5 | M | 5 | 2 | FV-FVII | FV: C: 39% | Positive family history | Post circumcision bleeding | 9 | 9 | – | rFVII (AryoSeven™, Aryogene, Iran) (OD) | Pos | Pos (Brother #4) |
| 6 | M | 20 | 1 | FV-FVII | FV: C: 3% | Epistaxis | Oral cavity bleeding | 15 | 15 | – | rFVII (AryoSeven™, Aryogene, Iran) (OD) | Pos | Pos (Brother #5) |
| 7 | F | 1 | 1 Mo | FVII-FXIID | FXII: C: 26% | Umbilical cord bleeding | Delayed wound healing | 11 | 5 | – | Confect™ Fibrogammin™ 250 IU/once a month | Pos | Neg |
| 8 | F | 30 | 14 | FXI-FXIID | FVII: C: 35% | Epistaxis | Delayed wound healing | 5 | 5 | – | None | Pos | Neg |
| 9 | F | 2 | 1 Mo | FV-FIXD | FV: <1% | Umbilical cord bleeding | Gum bleeding | 13 | 11 | – | FFP (PRO)(every 2 weeks) | Neg | Neg |
| 10 | M | 28 | 20 | FV-FXID | FV: 25% | GI bleeding | Epistaxis | 8 | 7 | – | TXA(OD) | Neg | Neg |
| 11 | M | 4 | 5 Mo | FID+BSS | CD41: 97.4% CD42: 1.4% CD61: 98.4% | Hematuria | Ecchymosis | 12 | 12 | – | Cryo (OD) Platelet (OD) | Neg | Neg |
| 12 | M | 18 | NA | FV-FVII | FV: 38% | Gum bleeding | Epistaxis | 5 | 5 | – | OD® | Pos | Neg |
| 13 | M | 23 | 7 | FVII-FIXD | FVII: C: 40% | Post-dental extraction bleeding | Gum bleeding | 4 | 3 | – | FIX (OD) | Neg | Neg |

(continued)
| N | Sex | Age (Year) | Age of diagnosis (Year) | Disorder | First laboratory assays* | Reason of diagnosis | Other clinical manifestations | BAT score | MCMDScore | PBACSscore | Type of treatment | Parental consanguinity | Family history ** |
|---|-----|------------|-------------------------|----------|--------------------------|---------------------|-----------------------------|-----------|------------|------------|------------------|---------------------|------------------|
| 14 | M   | 21         | 16                      | FVII-FXID | FVII: 30% FXI: 32%       | Menorrhagia         | Menorrhagia-\nEcchymosis \nDelayed wound healing \nOral cavity bleeding \nPost-dental extraction bleeding | 21        | 21         | 2090       | On-demand                 | Neg                 | Pos             |
| 15 | M   | 38         | NA                      | HA-HB    | FVII: C: 42% FXI: C: 22% | Gum bleeding        | Hematoma \nPost-dental extraction bleeding \nEpistaxis \nGI bleeding \nGum bleeding \nHemarthrosis \nEpistaxis \nHemarthrosis \nPost-operative bleeding | 20        | 20         | –          | FIX (OD) \nTXA(OD)     | Neg                 | Neg             |
| 16 | M   | 18         | 7                       | HA-HB    | FVII: C: 23% FXI: C: 33% | Post-operative bleeding | Ecchymosis \nDelayed wound healing \nPost dental extraction bleeding \nHemarthrosis | 19        | 19         | –          | FFP (OD)       | Pos                 | Neg             |
| 17 | M   | 32         | NA                      | HA-FXID  | FVIII:34% FXI: 42%       | Epistaxis           | Hemorrhagia \nBrussing \nGum bleeding \nHemarthrosis \nHemorrhagia \nPost-partum hemorrhage \nMenorrhagia | 12        | 12         | On-demand  | Pos             | Pos                 |                 |
| 18 | F   | 4          | 1                       | HA-FXID  | FVIII: 31% FXI: 37%      | Hematoma            | None                        | 4          | 4          | –          | On-demand       | Neg                 | Neg             |
| 19 | F   | 40         | 28                      | HA-FXID  | FVIII: 2.5% FXI: 28%     | Prolonged PTT       | Ecchymosis \nPost-dental extraction bleeding \nPost-partum hemorrhage \nMenorrhagia | 9          | 9          | 390        | FFP (OD)       | Neg                 | Pos             |
|   |     |            |                          |          |                          |                     |                                                                            |            |            |            |                  | Brothe have FXI deficiency |                 |
| 20 | F   | 9          | 9                       | FI-FVIID | FV: 0.4% FVII: 36%       | Brussing            | Delayed wound healing \nGum bleeding \nEpistaxis \nEcchymosis \nDental bleeding \nMenorrhagia | 4          | 4          | –          | None           | Pos                 | Neg             |
| 21 | F   | 54         | 50                      | FI-FVIID | FV: 0.61% FVII: 39%      | Menorrhagia         | Delayed wound healing \nGum bleeding \nEpistaxis \nEcchymosis \nDental bleeding \nMenorrhagia | 11         | 11         | 650        | Fibrinogen (OD)| Neg                 | Pos             |
| 22 | F   | 30         | 29                      | FV-FVII | FV:40% FVII: 13%         | Pre-operative screening | Brussing \nDelayed wound healing \nOral cavity bleeding \nPost-surgery bleeding | 9          | 8          | 326        | FFP (OD)       | Pos                 | Neg             |
| 23 | F   | 17         | 1                       | FI-FVIID | FV: <0.2% FVII: 37%      | Intracerebral hemorrhage | Brussing \nDelayed wound healing \nMenorrhagia | 10         | 9          | 709        | Fibrinogen (PRO-every 10 days 1 gr)| Pos                 | Neg             |

(continued)
Table 1 (continued)

| N  | Sex | Age (Year) | Age of diagnosis (Year) | Disorder | First laboratory assays* | Reason of diagnosis | Other clinical manifestation | BAT score | MCMD1 score | PBAC score | Type of treatment | Parental consanguinity | Family history ** |
|----|-----|------------|-------------------------|----------|-------------------------|--------------------|----------------------------|-----------|-------------|------------|---------------------|----------------------|------------------|
| 24 | F   | 11         | 10                      | FVII-FXD | FVII: C: 20% FX: C: 35% | Family history     | Epistaxis Brusing         | 5         | 5           | –          | None                | Pos                  | Brother (#25 and #26) |
| 25 | M   | 5          | 4                       | FVII-FXD | FVII: C: 18% FX: C: 10% | Family history     | Asymptomatic            | 0         | 0           | –          | None                | Pos                  | Brother (#24) |
| 26 | M   | 13         | 12                      | FVII-FXD | FVII: C: 19% FX: C: 37% | Family history     | Post-dental extraction bleeding | 4         | 4           | –          | None                | Pos                  | Father (#27) |
| 27 | M   | 41         | 36                      | FVII-FXD | FVII: C: <1% FX: C: 15% | Gum bleeding       | Epistaxis              | 13        | 13          | –          | rFVII (AryoSevenTM, Aryogene, Iran) (OD) | Pos                  | Sister (#24) |
| 28 | F   | 19         | NA                      | FVII-FXD | FVII: C: 22% FX: C: 37% | Prolonged PT and PTT | Post-operative bleeding Gum bleeding Delayed wound healing Ecchymosis GI bleeding Hamatoma CNS bleeding Gum bleeding – Epistaxis Post dental extraction bleeding | 7         | 7           | 110        | FFP(OD)            | Neg                  | Son Daughter |
| 29 | M***| 4          | 2 months                | FVII-FXD | FVII: C: <1% FX: C: 30% | CNS Bleeding       | Epcymosis              | 15        | 15          | –          | rFVII (AryoSevenTM, Aryogene, Iran) (OD) | Pos                  | Neg |
| 30 | M   | 39         | 27                      | FVIIID+: Low VWF | FVII: C: 33% FXIRC: 38% VWF:RCO: 30% VWF:Ag: 35% | Brusing           | Post-operative bleeding | 10        | 10          | –          | rFVII (AryoSevenTM, Aryogene, Iran) (OD) | Neg                  | Neg |
| 31 | M   | 14         | NA                      | FXID+: Type II M vWD | FXI: 10% FX: 15%vWF activity (Ricof): 28% VWF:Ag: 59% | Post-operative bleeding Oral cavity bleeding Epistaxis Brusing | 12        | 11          | –          | Haemate® (CSL Behring, Marburg, Germany) (OD) | Neg                  | Neg |
| 32 | F   | 46         | 44                      | FXID+: Low VWF | FXI: 5% FX: 15%vWF activity (Ricof): 39% VWF:Ag: 31% | Brusing           | Menorrhagia             | 11        | 10          | 575        | On-demand            | Neg                  | Neg |
| 33 | F   | 38         | 34                      | FV-FVIID | FVII: 16% FXI: 32% | Menorrhagia        | Oral cavity bleeding Epistaxis Brusing | 9         | 9           | 464        | TXA (OD)            | Neg                  | Neg |

F: Female, M: Male, LMWH: Low Molecular Weight Heparin, OD: on-demand, Pro: Prophylaxis, FFP: Fresh Frozen Plasma, TXA: tranexamic acid, CNS: central nervous bleeding, PTT: partial thromboplastin time, Pos: positive, Neg: negative, NA: not available.

*The normal ranges for laboratory assays are as follow: Fibrinogen: 1.5-4.5 g/dL, FV, FVII, FVIII, FIX, FX and FXI plasma level: 50-150%, VWF:Ag and VWF:RCO: 50-150%, platelet count: 150-450.

**The number in parenthesis is the patient number with same bleeding disorder.

***The number in parenthesis is the patient number with same bleeding disorder.

**** The FVII inhibitor titer is 14.7 and he died due to an extensive intracerebral hemorrhage.

The multimers pattern was normal. Forty-eight percent of the patients were the progeny of consanguineous marriages. A positive family history of bleeding was obtained from 11 patients (33.3%). The commonest reason for referral of these patients to ICHCC was a positive family history (15.1%) followed by epistaxis (12.1%) (Figure 1). Four patients were diagnosed because of a positive family history of bleeding. Life-threatening bleeding episodes including CNS bleeding (#23, 29), GI bleeding (#9), UC bleeding (#7,9), and miscarriage (#7,8) result in the diagnosis of 6 patients (18.1%). No life-threatening bleeding episodes were observed in the remaining patients (81.9%). The mean of ISTH-BAT and MCMD1 scores were 9.6 ± 4.79 and 9.1 ± 4.87, respectively (Table 2). Compared to the MCMD1 score, the mean ISTH-BAT score was higher (P <0.005). In female of menstrual age, the mean of PBAC score was 649.3 ± 554. Among these patients, menorrhagia was the main reason for their referral, in only 3 cases. Twenty-three (69.7%) received on-demand treatment, whereas 5 patients (15.1%) were put on prophylactic treatment.
FVII-type I VWD (5.3\%). There are various reports in the literature, reporting combined deficiency of FVII with F1, FV, FVIII, FIX, FX, FXI, and FXIII deficiencies.\textsuperscript{1,8-13} We identified a 1-year-old girl with combined FVII-FXIII deficiency, whose most salient complication was UC bleeding, just like patients with severe FXIII deficiency alone.\textsuperscript{14,15} Concomitant deficiency of FVII and FXIII is very rare and has only been reported in a single, male patient from Sistan and Baluchistan province in the south-eastern of Iran.\textsuperscript{1} This patient was actually born in neighboring Kerman province.

We also report 6 cases of combined FVII and FX deficiency, where 4 of them were members of the same family. A further case is a 2-month old FVII deficient boy who developed a FVII inhibitor after rFVIIa therapy-a very uncommon complication, who later died due to an extensive intracranial hemorrhage (ICH). According to the comprehensive study of Girolami et al. on the combination of FX deficiency with other coagulopathies, the most frequent type was with FVII deficiency.\textsuperscript{15} In our study, the commonest CBDs was FVII-FX deficiency. Furthermore, in 2004, Menegatti et al. reported 2 Iranian siblings, who were the progeny of a consanguineous marriage, and were affected with FVII and FX deficiency.\textsuperscript{16,17} An intriguing report by F.Zheng et al. encountered a 16-year-old Chinese boy without any history of bleeding diathesis, who had accidentally ingested a diphacinone rodenticide, which interferes with the synthesis of vitamin K-dependent coagulation factors. The patient received a vitamin K\textsubscript{1} injection, but his PT and APTT tests remained prolonged. After evaluation of FVII and FX activity together with molecular analysis, the patient was found to suffer from congenital combined FVII and FX deficiency.

### Table 2. Demographic and Clinical Information of the Patients with Congenital Combined Hemostatic Disorders.

| Population | Mean Age (year) | Mean age of the diagnosis (year) | Mean ISTH-BAT score | Mean MCMD 1 score | The most common clinical manifestation | The most common combined disorders |
|------------|-----------------|---------------------------------|---------------------|------------------|---------------------------------------|-----------------------------------|
| Male       | 22 ± 13         | 12.9 ± 12.7                     | 10.4 ± 6.1          | 10.5 ± 5.9       | Echymosis                             | FV-FVII deficiency (26.6%)        |
| Female     | 26.6 ± 16.49    | 21.4 ± 17                       | 8.8 ± 2.9           | 7.5 ± 2.2        | Echymosis                             | FXI deficiency-Low VWF (13.3%)    |
| Total      | 21.8 ± 14.81    | 14 ± 14.66                      | 9.6 ± 4.76          | 9.1 ± 4.87       | Echymosis                             | FV-FX deficient (18.1%)           |

Figure 1. Distribution of clinical manifestations in patients with combined bleeding disorders. PPH: Postpartum hemorrhage; GI bleeding: Gastrointestinal bleeding; UCB: Umbilical cord bleeding; CNS: Central nervous bleeding. Menorrhagia and PPH were estimated among the female of reproductive age.
The genes encoding FVII and FX are located on chromosome 13 (13q34), and combined FVII-FX deficiency is also reported in several cases with 13q34 deletion syndrome.\textsuperscript{19-21} We also reported 3 females with combined afibrinogenemia and FVII deficiency, who were investigated due to ICH, menorrhagia, and bruising, respectively. To our knowledge, there is only 1 similar, previous report of heterozygous dysfibrinogenemia and FVII deficiency. The patient in question was a 51-years-old man fortuitously diagnosed after pre-operative screening tests.\textsuperscript{22} We have also identified 6 cases with congenital coagulopathies due to FVII and FXI deficiency, associated with VWD, where 5 of them were affected by FXI deficiency, together with either type I VWD, or low VWF. The prevalence of congenital, combined coagulopathies, and VWD is not common in the medical literature, and their management appears to be challenging. A thorough study by Assattian et al. on VWD combined with HA, HB, FVII, XI, or XII deficiency, reported a wide range of clinical complications. Combined type I VWD and FXI deficiency presented with bleeding episodes typical of type I VWD, while the combination of type I and IIIN VWD with FVII deficiency caused severe bleeding diathesis.\textsuperscript{23} Two cases with combined HA and HB were identified in our study. Both were affected by clinically mild HA and HB. However, the ISTH-BAT score were 19 and 20. Previously, 2 separate cases were reported by Shetty et al. and Naderi et al. in 2001 and 2015, respectively.\textsuperscript{1,4} The former instance occurred in an Indian family, and the latter case was a 1-month-old boy from southeast of Iran, who developed bleeding after circumcision leading to a diagnosis of combined HA and HB. In 2016 Ivaškevičius et al. reported a case of HB which failed to respond to plasma-derived FIX concentrate prior to dental extraction, resulting in persistent bleeding. Further evaluation revealed a diagnosis of combined HA and HB deficiency at the unexpectedly advanced age of 42.\textsuperscript{24} We also found 3 cases of combined HA and HB deficiency. There are very few instances reported of this combined coagulopathy.\textsuperscript{25-27} In our study, we identified 1 case of combined FXI and FXII deficiency with a mild to moderate bleeding phenotype. Since FXII deficiency is not associated with bleeding tendency, episodes of hemorrhage must be attributed to the FXI deficiency.

For the first time, we have identified a patient with combined afibrinogenemia and Bernard Soulier syndrome (BSS), who was diagnosed early in her life, due to hematuria. Other studies have reported the co-expression of deficiencies of prekallikrein, FXI, and FXII with BSS.\textsuperscript{28-30}

All these findings indicate that the co-inheritance of hemostatic disorders in Iran is surprisingly greater than expected. All patients with congenital hemostatic disorders should be thoroughly evaluated, considering the patient’s phenotype and genotype, the personal and family medical history, together with the degree of consanguinity, in order to prevent misdiagnosis, and provide for proper care and management.

**Declaration of Conflicting Interests**
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**
The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iDs**
Seyed Esmaeil Ahmadi \(\text{https://orcid.org/0000-0002-1227-491X}\)
Shadi Tabibian \(\text{https://orcid.org/0000-0002-9875-8391}\)

**References**
1. Naderi M, Tabibian S, Hosseini MS, et al. Congenital combined deficiency of coagulation factors: a study of seven patients. *Blood Coagul Fibrinolysis*. 2015;26(1):59-62.
2. Franchini M, Marano G, Pupella S, et al. Rare congenital bleeding disorders. *Ann Transl Med*. 2018;6(17):331.
3. Dorgalaleh A, Alavi SER, Tabibian S, et al. Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran. *Hematology*. 2017;22(4):224-230.
4. Shetty S, Ghosh K, Parekh S, Mohanty D. Combined factor VIII and IX deficiency in a family. *Clin Lab Haematol*. 2001;23(3):201-204.
5. Nilsson IM, Magnusson S, Borchgrevink C. The duke and ivy methods for determination of the bleeding time. *Thromb Diath Haemorrh*. 1963;10(4):223-234.
6. Rassoulzadegan M, Ala F, Jazebi M, et al. Molecular and clinical profile of type 2 von Willebrand disease in Iran: a thirteen-year experience. *Int J Hematol*. 2020;111(4):1-9.
7. Brown DL. Congenital bleeding disorders. *Curr Probl Pediatr Adolesc Health Care*. 2005;35(2):38-62.
8. Girolami A, Venturelli R, Cella G, Virgolini L, Burul A. Combined hereditary deficiency of factors VII and VIII. *Acta Haematol*. 1976;55(3):181-191.
9. Bérubé C, Ofosu FA, Kelton JG, Blachman MA. A novel congenital haemostatic defect: combined factor VII and factor XI deficiency. *Blood Coagul Fibrinolysis*. 1992;3(4):357-360.
10. Pavlova A, Preisler B, Driesen J, et al. Congenital combined deficiency of coagulation factors VII and X – different genetic mechanisms. *Haemophilia*. 2015;21(3):386-391.
11. Girolami A, Zanon E, Bertomoro A, Gavasso S, Fadin M. Combined factor V and factor VII deficiency due to an independent segregation of the two defects. *Clin Appl Thromb Hemost*. 1999;5(2):136-138.
12. Shetty S, Ghosh K, Parekh S, Mohanty DJC, Haematology L. Combined factor VIII and IX deficiency in a family. *Clin Lab Haematol*. 2001;23(3):201-204.
13. Girolami A, Ruzzon E, Tezza F, Allemand E, Vettore S. Congenital combined defects of factor VII: a critical review. *Acta Haematol*. 2007;117(1):51-56.
14. Naderi M, Imani M, Eshghi P, et al. Factor XIII deficiency in sistan and baluchistan province %. *Sci J Iran Blood Transfus Organ*. 2013;10(3):282-288.
15. Girolami A, Ruzzon E, Tezza F, Scandellari R, Scapin M, Scarparo P. Congenital FX deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the literature. *Haemophilia*. 2008;14(2):323-328.
16. Menegatti M, Karimi M, Garagiola I, Mannucci P, Peyvandi F. A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency. *Am J Hematol*. 2004;77(1):90-91.

17. Boxus G, Slacmeulder M, Ninane J. [Combined hereditary deficiency in factors VII and X revealed by a prolonged partial thromboplastin time]. *Arch Pediatr*. 1997;4(1):44-47.

18. Zheng F, Jin Y, Wang M, Niu Z, Xu P, Xie HJT. Congenital combined deficiency of factor VII and X in a patient due to accidental dipiacetine intoxication. *Thromb Haemost*. 2011; 106(7):180-181.

19. Rath M, Najm J, Sirb H, et al. Large deletions play a minor but essential role in congenital coagulation factor VII and X deficiencies. *Hamostaseologie*. 2015;35(suppl 1):S36-S42.

20. Hewson MP, Carter JM. Severe congenital Factor VII deficiency associated with the 13q deletion syndrome. *Am J Hematol*. 2002; 71(3):232-233.

21. Chilcott JL, Russell G, Mumford AD. Combined deficiency of factors VII and X: clinical description of two cases and management of spinal surgery. *Haemophilia*. 2006;12(5):555-558.

22. Woo HI, Park IA, Lee KO, Kim SH, Kim HJ. Combined congenital dysfibrinogenemia and factor VII deficiency from mutations in the FGB and F7 genes. *Blood Coagul Fibrinolysis*. 2012;23(5):355-358.

23. Asatiani E, Kessler CM, On Behalf of the Directors of the Comprehensive Hemophilia Treatment Centers in R, III. Multiple congenital coagulopathies co-expressed with von Willebrand’s disease: the experience of hemophilia region III treatment centers over 25 years and review of the literature. *Haemophilia*. 2007;13(6):685-696.

24. Ivaškevičius V, Pezeshkpoor B, Biswas A, et al. Combined coagulation factor VIII and factor IX deficiency (CDF8F9) in a patient from Lithuania. *Hamostaseologie*. 2016;36(suppl 2):S29-S33.

25. Soff GA, Levin J, Bell WR. Familial multiple coagulation factor deficiencies. II. Combined factor VIII, IX, and XI deficiency and combined factor IX and XI deficiency: two previously uncharacterized familial multiple factor deficiency syndromes. *Semin Thromb Hemost*. 1981;7(2):149-169.

26. Berg LP, Varon D, Martinowitz U, Wieland K, Kakkar VV, Cooper DN. Combined factor VIII/factor XI deficiency may cause intra-familial clinical variability in haemophilia A among ashkenazi jews. *Blood Coagul Fibrinolysis*. 1994;5(1):59-62.

27. Lian EC, Deykin D, Harkness DR. Combined deficiencies of factor VIII (AHF) and factor XI (PTA). *Am J Hematol*. 1976; 1(3):319-324.

28. Ghosh K, Nair S, Shetty S, Rajapurkar M, Mohanty D. Co-existence of Bernard Soulier syndrome and factor XI deficiency in a family: a unified pathology? *Platelets*. 2005;16(2):85-89.

29. Shahverdi E, Abolghasemi H, Ahmadinejad M. Combined occurrence of Bernard-Soulier syndrome and prekallikrein deficiency. *Blood res*. 2017;52(3):229-231.

30. Korte W, Baumgartner C, Feldges A, et al. Coincidence of familial platelet glycoprotein Ib/IX deficiency (Bernard-Soulier syndrome), idiopathic autoantibody against platelet glycoprotein Ib/IX, familial appearance of antiphospholipid antibodies, and familial factor XII deficiency. *Ann Hematol*. 1994;68(2):101-104.